Assessment of the Degree of Left Atrial Fibrosis in Patients with Different Forms of Atrial Fibrillation

DOI: https://doi.org/10.63181/ujcvs.2025.33(2).62-69
Keywords: Catheter ablation, cryoballoon ablation, heart failure, atrial cardiomyopathy, electrical cardioversion, pulsed field ablation, pacemaker

Abstract

Atrial fibrillation (AF) is the most common type of cardiac arrhythmia, which has a significant impact on the health of patients worldwide. Left atrial fibrosis (LAF) is considered an irreversible form of remodeling that occurs in response to inflammation, stretching, or overload of the left atrium. The prevalence and degree of LAF may be associated with the prognosis and treatment outcomes after catheter ablation.

Aim. To determine whether the degree of left atrial fibrosis is associated with the progression of atrial fibrillation.

Materials and methods. During the period from January 2023 to December 2024, the State Research Institute of Cardiology named after M.M. Amosov National Academy of Medical Sciences of Ukraine performed 58 MRI studies with late contrast enhancement with gadolinium to study the degree of fibrosis of different chambers of the heart. Thirty-six of these patients were diagnosed with AF. In 12 patients, catheter ablation for atrial fibrillation was subsequently performed (radiofrequency, cryoballoon ablation, or pulsed field ablation). In 10, an attempt at electrical cardioversion without catheter intervention was performed.

Results. Among the 34 patients included in the study, 13 (38 %) had paroxysmal AF, 14 (41 %) had persistent AF, and 7 (21 %) had permanent AF. Among the patients with paroxysmal AF, 9 (69 %) had stage I of left atrial fibrosis (LAF), 4 (31 %) had LAF stage II. No patients with LAF stage III-IV were observed in the paroxysmal AF group. In the persistent AF group (n = 14, 41 %), LAF stage I was observed in 4 (29 %) patients, LAF stage II in 8 (57 %), and LAF stage III and IV in 1 (7 %) patient in each group. In the patients with permanent AF (n = 7, 21 %), no patients with LAF stage I were observed. LAF stage II was observed in 4 (57 %) patients, LAF stage III in 2 (28 %), and LAF stage IV in 1 (14 %). The analysis showed a statistically significant decrease in left ventricular ejection fraction in patients with progressive AF. In the paroxysmal group, the mean LVEF was 55.75 ± 11.05 %, while in patients with persistent AF it decreased to 47.46 ± 13.88 %, and in chronic AF it decreased to 36.29 ± 12.08 % (p = 0.018).

Conclusions. According to our results, the degree of fibrosis of the left atrium correlates with the stage of progression of atrial fibrillation.

References

  1. Linz D, Gawalko M, Betz K, Hendriks JM, Lip GYH, Vinter N, Guo Y, Johnsen S. Atrial fibrillation: epidemiology, screening and digital health. Lancet Reg Health Eur. 2024 Feb 1;37:100786. doi: 10.1016/j.lanepe.2023.100786
  2. Lippi G, Sanchis-Gomar F, Cervellin G. Global epidemiology of atrial fibrillation: An increasing epidemic and public health challenge. Int J Stroke. 2021 Feb;16(2):217-221. doi: 10.1177/1747493019897870
  3. Isabelle C Van Gelder, Michiel Rienstra, Karina V Bunting, Ruben Casado-Arroyo, Valeria Caso, Harry J G M Crijns, ESC Scientific Document Group, et al. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): Developed by the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC), with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Endorsed by the European Stroke Organisation (ESO). European Heart Journal. 2024 September;45(36):3314–3414. https://doi.org/10.1093/eurheartj/ehae176
  4. Elsheikh S, Hill A, Irving G, Lip GYH, Abdul-Rahim AH. Atrial fibrillation and stroke: State-of-the-art and future directions. Curr Probl Cardiol. 2024 Jan;49(1 Pt C):102181. doi: 10.1016/j.cpcardiol.2023.102181
  5. Bergau L, Bengel P, Sciacca V, Fink T, Sohns C, Sommer P. Atrial Fibrillation and Heart Failure. J Clin Med. 2022 Apr 29;11(9):2510. doi: 10.3390/jcm11092510
  6. Martymianova L, Kamenska E, Bulyha A, & Serdyuk K. Atrial fibrillation with thrombotic complications. Justification of the diagnosis and treatment regimen according to evidence-based medicine (clinical case). The Journal of V. N. Karazin Kharkiv National University. Series Medicine. 2024;32(4(51): 571-583. https://doi.org/10.26565/2313-6693-2024-51-11
  7. Zolotarova T, Bilchenko O, Volkov D, Pasyura I, & Prylutska K. Peculiarities of pharmacotherapy of chronic heart failure with retained left ventricular efficiency and associated atrial fibrilation depending on the method of heart rhythm control. The Journal of V. N. Karazin Kharkiv National University, Series "Medicine&quot. 2022; (44). https://doi.org/10.26565/2313-6693-2022-44-07
  8. Ioannidis P, Zografos T, Christoforatou E, Kouvelas K, Tsoumeleas A, Vassilopoulos C. The Electrophysiology of Atrial Fibrillation: From Basic Mechanisms to Catheter Ablation. Cardiol Res Pract. 2021 Jun 5;2021:4109269. doi: 10.1155/2021/4109269
  9. Vinciguerra M, Dobrev D, Nattel S. Atrial fibrillation: pathophysiology, genetic and epigenetic mechanisms. Lancet Reg Health Eur. 2024 Feb 1;37:100785. doi: 10.1016/j.lanepe.2023.100785
  10. Ma J, Chen Q, Ma S. Left atrial fibrosis in atrial fibrillation: Mechanisms, clinical evaluation and management. J Cell Mol Med. 2021 Mar;25(6):2764-2775. https://doi.org/10.1111/jcmm.16350 .
  11. Sohns C, Marrouche NF. Atrial fibrillation and cardiac fibrosis. Eur Heart J. 2020 Mar 7;41(10):1123-1131. doi: 10.1093/eurheartj/ehz786
  12. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2024 Jan 2;149(1):e167. doi: 10.1161/CIR.0000000000001207
  13. Jordi Heijman, Stefan H Hohnloser, A John Camm, Antiarrhythmic drugs for atrial fibrillation: lessons from the past and opportunities for the future. EP Europace. 2021 April;23(2):ii14–ii22. https://doi.org/10.1093/europace/euaa426
  14. Natale A, Mohanty S, Sanders P, Anter E, Shah A, Al Mohani G, Haissaguerre M. Catheter ablation for atrial fibrillation: indications and future perspective. Eur Heart J. 2024 Nov 7;45(41):4383-4398. https://doi.org/10.1093/eurheartj/ehae618
  15. Kawamura I, Koruth J. Novel Ablation Catheters for Atrial Fibrillation. Rev Cardiovasc Med. 2024 May 23;25(5):187. doi: 10.31083/j.rcm2505187
  16. Kueffer T, Stettler R, Maurhofer J, Madaffari A, Stefanova A, Iqbal SUR, et al. Pulsed-field vs cryoballoon vs radiofrequency ablation: Outcomes after pulmonary vein isolation in patients with persistent atrial fibrillation. Heart Rhythm. 2024 Aug;21(8):1227-1235. doi: 10.1016/j.hrthm.2024.04.045
  17. Maurhofer J, Kueffer T, Madaffari A, Stettler R, Stefanova A, Seiler J, Thalmann G, Kozhuharov N, Galuszka O, Servatius H, Haeberlin A, Noti F, Tanner H, Roten L, Reichlin T. Pulsed-field vs. cryoballoon vs. radiofrequency ablation: a propensity score matched comparison of one-year outcomes after pulmonary vein isolation in patients with paroxysmal atrial fibrillation. J Interv Card Electrophysiol. 2024 Mar;67(2):389-397. doi: 10.1007/s10840-023-01651-4
  18. Kobori A, Sasaki Y, Pak M, Ishikura M, Murai R, Okada T, et al. Comparison of Cryoballoon and Contact Force-Sensing Radiofrequency Ablation for Persistent Atrial Fibrillation in Clinical Practice. Circ J. 2022 Jan 25;86(2):290-298. doi: 10.1253/circj.CJ-21-0608
  19. Metzner A, Fiala M, Vijgen J, Ouss A, Gunawardene M, Hansen J, Kautzner J, Schmidt B, Duytschaever M, Reichlin T, Blaauw Y, Sommer P, Vanderper A, Achyutha AB, Johnson M, Raybuck JD, Neuzil P. Long-term outcomes of the pentaspline pulsed-field ablation catheter for the treatment of paroxysmal atrial fibrillation: results of the prospective, multicentre FARA-Freedom Study. Europace. 2024 Mar 1;26(3):euae053. https://doi.org/10.1093/europace/euae053
  20. Marrouche NF, Wazni O, McGann C, Greene T, Dean JM, Dagher L, et al; DECAAF II Investigators. Effect of MRI-Guided Fibrosis Ablation vs Conventional Catheter Ablation on Atrial Arrhythmia Recurrence in Patients With Persistent Atrial Fibrillation: The DECAAF II Randomized Clinical Trial. JAMA. 2022 Jun 21;327(23):2296-2305. doi: 10.1001/jama.2022.8831
  21. Li CY, Zhang JR, Hu WN, Li SN. Atrial fibrosis underlying atrial fibrillation (Review). Int J Mol Med. 2021 Mar;47(3):9. doi: 10.3892/ijmm.2020.4842
  22. Anastasia Xintarakou, Stylianos Tzeis, Stelios Psarras, Dimitrios Asvestas, Panos Vardas, Atrial fibrosis as a dominant factor for the development of atrial fibrillation: facts and gaps. EP Europace. 2020 March;22(3): 342–351. https://doi.org/10.1093/europace/euaa009
  23. Tore D, Faletti R, Biondo A, Carisio A, Giorgino F, Landolfi I, et al. Role of Cardiovascular Magnetic Resonance in the Management of Atrial Fibrillation: A Review. Journal of Imaging. 2022; 8(11):300. https://doi.org/10.3390/jimaging8110300
  24. Chahine Y, Chamoun N, Kassar A, Bockus L, Macheret F, Akoum N. Atrial fibrillation substrate and impaired left atrial function: a cardiac MRI study. Europace. 2024 Nov 1;26(11):euae258. doi: 10.1093/europace/euae258
  25. Li L, Zimmer VA, Schnabel JA, Zhuang X. Medical image analysis on left atrial LGE MRI for atrial fibrillation studies: A review. Med Image Anal. 2022 Apr;77:102360. doi: 10.1016/j.media.2022.102360
  26. Tonko J, Lee A, Mannakkara N, Williams SE, Razavi R, Bishop M, et al. Structural phenotyping in atrial fibrillation with combined cardiac CT and atrial MRI: Identifying and differentiating individual structural remodelling types in AF. J Cardiovasc Electrophysiol. 2024 Sep;35(9):1788-1796. doi: 10.1111/jce.16357
  27. Hopman LHGA, Bhagirath P, Mulder MJ, Eggink IN, van Rossum AC, Allaart CP, et al. Quantification of left atrial fibrosis by 3D late gadolinium-enhanced cardiac magnetic resonance imaging in patients with atrial fibrillation: impact of different analysis methods. Eur Heart J Cardiovasc Imaging. 2022 Aug 22;23(9):1182-1190. doi: 10.1093/ehjci/jeab245
  28. Lamy J, Taoutel R, Chamoun R, Akar J, Niederer S, Mojibian H, et al. Atrial fibrosis by cardiac MRI is a correlate for atrial stiffness in patients with atrial fibrillation. Int J Cardiovasc Imaging. 2024 Jan;40(1):107-117. doi: 10.1007/s10554-023-02968-x
  29. Habibi M, Chrispin J, Spragg DD, Zimmerman SL, Tandri H, Nazarian S, et al. Utility of Cardiac MRI in Atrial Fibrillation Management. Card Electrophysiol Clin. 2020 Jun;12(2):131-139. doi: 10.1016/j.ccep.2020.02.006
  30. Regmi MR, Bhattarai M, Parajuli P, Botchway A, Tandan N, Abdelkarim J, Labedi M. Prediction of Recurrence of Atrial Fibrillation Post-ablation Based on Atrial Fibrosis Seen on Late Gadolinium Enhancement MRI: A Metaanalysis. Curr Cardiol Rev. 2023;19(3):e051222211571. doi: 10.2174/1573403X19666221205100148
  31. Moro C, Hernández-Madrid A, Matía R. Non-antiarrhythmic drugs to prevent atrial fibrillation. Am J Cardiovasc Drugs. 2010;10(3):165-73. doi: 10.2165/11537270-000000000-00000
  32. Tung R, Burri H. Role of conduction system pacing in ablate and pace strategies for atrial fibrillation. Eur Heart J Suppl. 2023 Nov 9;25(Suppl G):G56-G62. https://doi.org/10.1093/eurheartjsupp/suad119
Published
2025-06-25
How to Cite
1.
Perepeka EO, Bodnarevska EV, Ishchenko MS, Kravchuk BB. Assessment of the Degree of Left Atrial Fibrosis in Patients with Different Forms of Atrial Fibrillation. ujcvs [Internet]. 2025Jun.25 [cited 2025Jun.28];33(2):62-9. Available from: https://www.cvs.org.ua/index.php/ujcvs/article/view/732
Issue
Ukrainian Journal of Cardiovascular Surgery Vol 33 No 2 2025
Section
RHYTHM DISTURBANCES

Most read articles by the same author(s)

1 2 > >>